Status:

RECRUITING

Lactobreath: A Study to Diagnose Lactose Intolerance Using Breath Markers

Lead Sponsor:

ETH Zurich

Collaborating Sponsors:

Agroscope Liebefeld-Posieux Research Station ALP

Swiss Allergy Centre

Conditions:

Lactose Intolerance

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Food intolerances affect many people and can cause discomfort and dietary challenges. One common cause is difficulty digesting certain carbohydrates called FODMAPs. Diagnosing food intolerance is ofte...

Detailed Description

Genetic and lactose tolerance screening For all eligible participants, a screening home test will be conducted. The home screening test kit will contain lactose powder and accompanying information in ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Men and women
  • Swiss and non-Swiss living in the Zurich area (if necessary, beyond Zürich in Switzerland),
  • Ability/desire to provide informed consent and partake in the procedures of the study
  • Aged 18-65 years at screening
  • Agreement to refrain from all other treatments and products used for dairy intolerance (e.g., Lactaid® dietary supplements) during study involvement
  • Willing to return for all study visits and complete all study-related procedures, including fasting before and during the intervention
  • Able to understand and provide written informed consent in English and/or German.
  • Exclusion criteria:
  • Allergic to milk
  • Currently pregnant
  • Currently lactating
  • Cigarette smoking or other use of tobacco or nicotine-containing products within 3 months of screening
  • Diagnosed with any of the following disorders known to be associated with abnormal GI motility: gastroparesis, amyloidosis, neuromuscular diseases (including Parkinson's disease), collagen vascular diseases, alcoholism, uremia, malnutrition, or untreated hypothyroidism
  • History of surgery that alters normal GI tract function, including but not limited to: GI bypass surgery, bariatric surgery, gastric banding, vagotomy, fundoplication, pyloroplasty (N.B. history of uncomplicated abdominal or GI surgeries such as removal of an appendix \>12 months before screening will not be excluded)
  • Suspected obscure GI bleeding
  • Past or present: organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, coeliac disease, diverticular disease, inflammatory bowel disease, strictures (suspected or known), fistulas, or any GI obstruction, gastroparesis, history of gastric bezoar or any other medical condition with symptoms that could confound collection of adverse events
  • Diabetes mellitus
  • Congestive heart failure
  • Human immunodeficiency virus, hepatitis B, or hepatitis C
  • Body mass index \> 35 kg/m2
  • Swallowing disorders or dysphagia to food or pills
  • Presence of implantable or portable electro-mechanical medical devices (e.g. pacemakers)
  • Recent bowel preparation for endoscopic or radiologic investigation within 4 weeks of screening (e.g., colonoscopy preparation)
  • Chronic antacid and/or proton pump inhibitor use
  • Recent use of systemic antibiotics, defined as use within 2 months prior to screening
  • History of ethanol (alcohol) and/or drug abuse in the past 12 months
  • Patients with severe irritable bowel syndrome (IBS) (i.e., IBS Symptom Severity Score \>400)
  • Dietary restrictions including vegan or vegetarian diet.
  • Any other conditions/issues noted by the study staff and/or Principal Investigator that would impact participation and/or protocol compliance.
  • Previous enrollment in another clinical trial within the last 3 months.
  • Results of the screening test showing GI symptoms in response to lactose ingestion and genetic LP.

Exclusion

    Key Trial Info

    Start Date :

    June 24 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2025

    Estimated Enrollment :

    120 Patients enrolled

    Trial Details

    Trial ID

    NCT06177938

    Start Date

    June 24 2024

    End Date

    December 1 2025

    Last Update

    July 8 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    ETH Zurich

    Zurich, Canton of Zurich, Switzerland, 8093